Inserm UMR1245 - Cancer and Brain Genomics (CBG) - Université de Rouen Normandie

What Inserm UMR1245 - Cancer and Brain Genomics (CBG) - Université de Rouen Normandie does

Inserm UMR1245 - Cancer and Brain Genomics (CBG) is a French public research laboratory (Unité Mixte de Recherche) jointly supervised by Inserm and the Université de Rouen Normandie, with a stated mission to improve diagnosis and care of cancers and neurological diseases by studying genetic determinism and identifying specific biomarkers using genomic and multi-omics tools. The unit is organized around five research teams focused on hereditary cancer predisposition, lymphoma and solid tumor genomics, brain disorder genomics, neurodevelopmental disorder epigenetics, and brain tumor biology. It serves academic and clinical stakeholders including physicians and researchers at Rouen University Hospital (CHU de Rouen), the Henri Becquerel Comprehensive Cancer Center, the François Baclesse Cancer Center in Caen, and a network of European and national consortia (Institut Curie for FroG, LYSA Cooperative Group, European Reference Network Genturis, ADES Consortium, ENIGMA, FrenchConnect, EUFASD).

The unit operates a platform-centered infrastructure. Core technology assets include the ASGARD Platform (Illumina MiSeq/Nextseq550/Novaseq6000 plus PacBio Revio and Nanopore long-read sequencers, robotic library preparation, digital PCR and DNA methylation tools), the CEREBRO computing cluster (over 700 threads, 1.5 PB CEPH-FS storage), the PRIMACEN imaging platform, and laboratory capability for human induced pluripotent stem cell culture, CRISPR/Cas9 editing, organoid differentiation, and small-animal work including in utero electroporation, electrophysiology, and optogenetics. The lab has produced a suite of registered bioinformatics tools (SpliceLauncher, LORID, SOSTAR, DIVA, CircNet, SPiP) and the LD-RTPCR LymphoSign molecular classification assay, the latter licensed to Sophia Genetics for commercial use.

CBG's business model is that of a public research institution rather than a commercial entity: funding is provided by supervising bodies (Inserm, Université de Rouen Normandie), competitive grants (ANR, EU Horizon/FEDER, Normandy Region, CPER, Ligue contre le Cancer), the CALYM Carnot Institute, and collaborative research agreements. Revenue is augmented, but not substituted, by technology licensing (Sophia Genetics, Genexpath) and a planned 2026 start-up with Normandie Valorization to commercialize a 2024 patent (WO/2025/087667) on peptide inhibitors of Filamin A / UT receptor interaction for glioblastoma treatment. Distribution of research output occurs through peer-reviewed publications (HAL open access repository), conference participation (ICCTF, ANOCEF, FENS, Cancéropôle meetings), and embedded clinical-translational channels rather than commercial sales.

Name

Inserm UMR1245 - Cancer and Brain Genomics (CBG) - Université de Rouen Normandie

Legal name

Inserm UMR1245 - Cancer and Brain Genomics (CBG)

Website

https://cbg.univ-rouen.fr

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

Inserm UMR1245 Cancer and Brain Genomics (CBG) is a French public research laboratory jointly supervised by Inserm and Université de Rouen Normandie that studies genetic determinism and biomarkers for cancers and neurological diseases, operating five research teams and genomics/bioinformatics platforms serving academic and clinical collaborators.

Ownership category

akta.pro rank

Product category

Academic Genomics Research and Multi-Omics Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)

SIC

Laboratory Analytical Instruments (3826), Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)

akta.pro secondary industries

Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI), Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics) (HLAAANAF), Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE), Epigenomics & Chromatin Profiling Services (HLAGANAF), Transcriptomics & Gene Expression Profiling Services (HLAGANAE), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• Genomic sequencing services
• Cancer genomics research
• Neurogenetics research
• Bioinformatics tools development
• Clinical genomics diagnostics

Headquarters

HQ city

Rouen

HQ country

France

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations

Distribution channels3 records

Marketing channels3 records

Core offering

Inserm UMR1245 CBG is a public research laboratory that studies the genetic determinism of cancers and neurological diseases and develops specific biomarkers using multi-omics tools. It delivers advanced next-generation sequencing services through the ASGARD platform (short-read Illumina and long-read Pacbio/Nanopore sequencers), high-performance bioinformatics via the CEREBRO cluster, hiPSC/CRISPR-based disease modeling, and specialized bioinformatics software (SpliceLauncher, LORID, SOSTAR, SPiP, CircNet, DIVA) for variant and splicing analysis. The Cancer and Cognition Platform additionally addresses cognitive sequelae of cancer and its treatments, supporting translational research from rare disease analysis to precision medicine tools.

Product overview

Inserm UMR1245 CBG is a research laboratory organized as a platform-centered infrastructure providing genomic and bioinformatics services. The core offering centers on the ASGARD high-throughput sequencing platform for research and clinical diagnostics, supported by the CEREBRO computing cluster for data processing. The laboratory also develops specialized bioinformatics tools (SpliceLauncher, CircNet, LORID, SOSTAR, DIVA) and molecular tests (LD-RTPCR LymphoSign). The Cancer and Cognition Platform addresses cognitive impacts of cancer treatments. Five research teams (Hereditary Cancer Predispositions, Lymphomas and Solid Tumors, Brain Disorders, Neurodevelopmental Disorders, and Brain Tumor Biology) utilize these platforms for translational research in cancer genetics and neurogenetics.

Differentiator

Problem solved

Functional benefit

Brands

• ASGARD Platform: Advanced Sequencing solutions and Genomic Analyses for Research and Diagnosis - high-throughput sequencing platform
• Cancer and Cognition Platform
• NeuroGlio

Products and services

• ASGARD Platform (Advanced Sequencing solutions and Genomic Analyses for Research and Diagnosis) High-throughput genomic sequencing service for research and diagnostic applications, offering short-read sequencing on Illumina Miseq, Nextseq550, and Novaseq6000 instruments, long-read sequencing on PacBio Revio and ONT P2 Solo, library preparation, and bioinformatics analysis; serves researchers and clinicians including the CHU de Rouen diagnostic genetics service.
• CEREBRO Computing Cluster High-performance computing and storage cluster providing more than 700 computational threads and 1.5 PB of CEPH-FS type storage dedicated to processing and analyzing genomic sequencing data for unit and collaborative research projects.
• Cancer and Cognition Platform Multidisciplinary platform for assessing and managing cognitive complaints and neuropsychological disorders induced by cancer and its treatments, combining preclinical research, neuropsychological expertise (Prof. F. Joly, Centre François Baclesse ANTICIPE Unit 1080), clinical studies, and biomarker analysis for oncology patients and clinicians.
• SpliceLauncher Bioinformatics software for the detection, annotation, and relative quantification of alternative splicing junctions from RNA-seq data; used by researchers working on variant interpretation and splicing effects.
• LD-RTPCR LymphoSign Signature Molecular classification test for lymphomas that combines targeted transcriptome data with a Random Forest machine learning algorithm to subtype disease; licensed to Sophia Genetics for industrial deployment in molecular diagnostics.
• LORID Bioinformatics Tool Software tool for the detection of deep intronic variants in genomic data, supporting interpretation of non-coding variation in hereditary disease and cancer predisposition studies.
• SOSTAR Bioinformatics Tool Software tool for splicing analysis, used to evaluate transcript-level effects of genetic variants.
• SPiP (Splicing Pipeline) Pipeline tool for splicing analysis used in the interpretation of genetic variation impact on RNA processing.
• CircNet Bioinformatics Tool Software tool for studying circular RNAs, supporting non-coding RNA analysis in disease research.
• DIVA Bioinformatics Tool Software tool for the research and detection of deep intronic variants, complementing the unit's variant interpretation pipeline alongside LORID.

Quantifiable outcome

• Development of GIScar genomic instability score for predicting sensitivity to maintenance Olaparib for ovarian cancer
• +2 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature6 records

Partnerships

14 partnerships are on record, tiered minor and core.

• Preventable (H2022-2025)minorStrategic or Co-development Partner · 1 January 2022Participation in European H2020 study on preventable cancers with medico-economic focus
• Institut CuriecoreStrategic or Co-development PartnerCollaborative development and management of FroG (French Oncogenetics Database), a reference database in oncogenetics shared with Institut Curie
• LYSA Cooperative GroupcoreStrategic or Co-development PartnerContributes to analysis of biological samples from numerous clinical trials (SENIOR, GAINED, REMARC, Epi-RCHOP, VALYM) supported by CALYM Carnot Institute
• European Reference Network Genturis (ERN Genturis)coreStrategic or Co-development PartnerActive participation in European network for genetic tumor risk syndromes
• ENIGMA ConsortiumcoreStrategic or Co-development PartnerInternational collaboration in genetics and cancer research
• ADES (Alzheimer Disease European Sequencing) ConsortiumcoreStrategic or Co-development PartnerEuropean consortium co-led by the unit for Alzheimer disease genetic research, focusing on exome and genome sequencing
• FrenchConnectcoreStrategic or Co-development PartnerActive member of national group aiming to standardize and develop ctDNA sequencing activity in lymphomas
• ANPGM (Association nationale des Praticiens de Génétique Moléculaire)minorStrategic or Co-development PartnerNational collaboration in molecular genetics practice
• GGC (Groupe Génétique et Cancer)minorStrategic or Co-development PartnerNational collaboration group for genetics and cancer
• Normandie ValorizationminorStrategic or Co-development PartnerPlanned start-up collaboration for patent WO/2025/087667 on UT receptor inhibitors for glioblastoma treatment
• Cancéropôle Nord-OuestcoreStrategic or Co-development PartnerMain support for Cancer and Cognition platform addressing links between cancer and brain, with axis 4 on cancer and cognition
• Centre François Baclesse (ANTICIPE Unit 1080)coreStrategic or Co-development PartnerPartnership with Prof. F. Joly for Cancer and Cognition platform providing neuropsychological and clinical research expertise
• EUFASDcoreStrategic or Co-development PartnerInternational network member and organizing committee for EUFASD 2026 Congress on fetal alcohol spectrum disorders
• GIS Autism and NDDcoreStrategic or Co-development PartnerMember of national network for autism and neurodevelopmental disorders research

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Sophia Genetics: AI-driven genomics company that has licensed CBG's LD-RTPCR LymphoSign signature. Comparable as a clinical genomics interpretation platform player, though operating commercially across multiple cancer types.

Direct peers

• Centre François Baclesse: Caen-based CLCC that partners with CBG on the Cancer and Cognition Platform and houses one of CBG's research teams. Direct peer in Normandy oncology research and clinical genomics.
• Plateforme Génomique Institut Gustave Roussy / Genomic Core Facilities: Genomic sequencing and bioinformatics platforms within major French cancer centers that compete for regional and national sequencing service contracts in oncology research, comparable to CBG's ASGARD platform.
• Institut de Recherche en Cancérologie de Montpellier (IRCM / INSERM U1194): Inserm-affiliated cancer research unit in Montpellier with similar focus on oncology genomics, biomarkers, and translational research. Comparable as a French Inserm UMR with multi-omics and precision medicine orientation.
• Institut Curie: Major French cancer research center with which CBG co-develops and manages the FroG (French Oncogenetics Database). Highly comparable in oncogenetics and translational cancer genomics mission, though at much larger scale.

Broad incumbents

• Gustave Roussy: Largest European cancer center combining research, treatment, and teaching. Comparable in integrating genomics-driven precision oncology with clinical care, though with substantially broader scope and resources.
• European Bioinformatics Institute (EMBL-EBI): International bioinformatics institute providing open-access genomic data tools and infrastructure. Comparable in maintaining large-scale bioinformatics compute and pipelines for life science research, though at a much larger institutional scale.
• Wellcome Sanger Institute: Leading genomics and bioinformatics research institute with large-scale sequencing capabilities. Comparable in applying high-throughput sequencing and multi-omics to disease research, though with substantially greater funding and capacity.

Regional players

• Centre Léon Bérard: French Comprehensive Cancer Center (CLCC) in Lyon focused on oncology research and care. Comparable as a CLCC-affiliated cancer genomics research entity, though geographically focused on the Auvergne-Rhône-Alpes region.

Others

• France Génomique: National consortium coordinating French genomics platforms and providing sequencing services. Comparable as an enabling infrastructure network of which CBG's ASGARD platform is part of the broader French genomics ecosystem.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/inserm-umr1245-cancer-and-brain-genomics-cbg

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Inserm UMR1245 - Cancer and Brain Genomics (CBG) - Université de Rouen Normandie